Virdante Pharma Raises $47 Million
Virdante Pharmaceuticals, a Cambridge, Mass.-based developer of technology to increase the anti-inflammatory potency of plasma-derived intravenous immune globulin, has expanded its Series A funding to $47.75 million. Thomas, McNerney & Partners led the new tranche, and was joined by Osage Partners and return backers Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.
29 October 2009•4 mins read
